201 related articles for article (PubMed ID: 22981913)
21. Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An in vitro study in 2D and 3D prostate cancer models.
Martinez de Pinillos Bayona A; Woodhams JH; Pye H; Hamoudi RA; Moore CM; MacRobert AJ
Cancer Lett; 2017 May; 393():68-75. PubMed ID: 28223166
[TBL] [Abstract][Full Text] [Related]
22. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
23. Development of resistance to photodynamic therapy (PDT) in human breast cancer cells is photosensitizer-dependent: Possible mechanisms and approaches for overcoming PDT-resistance.
Olsen CE; Weyergang A; Edwards VT; Berg K; Brech A; Weisheit S; Høgset A; Selbo PK
Biochem Pharmacol; 2017 Nov; 144():63-77. PubMed ID: 28784290
[TBL] [Abstract][Full Text] [Related]
24. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
26. Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin.
Selbo PK; Sivam G; Fodstad O; Sandvig K; Berg K
Int J Cancer; 2000 Sep; 87(6):853-9. PubMed ID: 10956397
[TBL] [Abstract][Full Text] [Related]
27. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
[TBL] [Abstract][Full Text] [Related]
28. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells.
Yip WL; Weyergang A; Berg K; Tønnesen HH; Selbo PK
Mol Pharm; 2007; 4(2):241-51. PubMed ID: 17263556
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
30. Dendrimer phthalocyanine-encapsulated polymeric micelle-mediated photochemical internalization extends the efficacy of photodynamic therapy and overcomes drug-resistance in vivo.
Lu HL; Syu WJ; Nishiyama N; Kataoka K; Lai PS
J Control Release; 2011 Nov; 155(3):458-64. PubMed ID: 21689700
[TBL] [Abstract][Full Text] [Related]
31. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
Savellano MD; Pogue BW; Hoopes PJ; Vitetta ES; Paulsen KD
Cancer Res; 2005 Jul; 65(14):6371-9. PubMed ID: 16024640
[TBL] [Abstract][Full Text] [Related]
32. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy.
Selbo PK; Sivam G; Fodstad O; Sandvig K; Berg K
Int J Cancer; 2001 Jun; 92(5):761-6. PubMed ID: 11340584
[TBL] [Abstract][Full Text] [Related]
33. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
34. Photophysical and photobiological properties of a sulfonated chlorin photosensitiser TPCS(2a) for photochemical internalisation (PCI).
Wang JT; Berg K; Høgset A; Bown SG; MacRobert AJ
Photochem Photobiol Sci; 2013 Mar; 12(3):519-26. PubMed ID: 23232550
[TBL] [Abstract][Full Text] [Related]
35. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications.
Berg K; Selbo PK; Weyergang A; Dietze A; Prasmickaite L; Bonsted A; Engesaeter BØ; Angell-Petersen E; Warloe T; Frandsen N; Høgset A
J Microsc; 2005 May; 218(Pt 2):133-47. PubMed ID: 15857375
[TBL] [Abstract][Full Text] [Related]
36. Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization.
Fretz MM; Høgset A; Koning GA; Jiskoot W; Storm G
Pharm Res; 2007 Nov; 24(11):2040-7. PubMed ID: 17541733
[TBL] [Abstract][Full Text] [Related]
37. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
[TBL] [Abstract][Full Text] [Related]
38. Photochemical internalization (PCI)-mediated enhancement of bleomycin cytotoxicity by liposomal mTHPC formulations in human head and neck cancer cells.
Peng W; Samplonius DF; de Visscher S; Roodenburg JL; Helfrich W; Witjes MJ
Lasers Surg Med; 2014 Oct; 46(8):650-8. PubMed ID: 25174329
[TBL] [Abstract][Full Text] [Related]
39. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
40. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K
Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
